Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | OPRL1 | P41146 | 5/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.35 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.33 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.33 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24040191 | 0.90 | OPRL1 (0.37) | TSHROPRL1OPRM1L3MBTL3L3MBTL1 | |
| SCHEMBL20655375 | 0.83 | TSHR (0.37) | TSHRMEN1KMT2AALDH1A1NPSR1 | |
| SCHEMBL803602 | 0.82 | KDM2B (0.39) | TSHRMEN1KMT2AALDH1A1OPRM1 | |
| SCHEMBL25463735 | 0.79 | OPRL1 (0.38) | KMT2AOPRL1OPRM1L3MBTL3L3MBTL1 | |
| SCHEMBL20094684 | 0.78 | TSHR (0.35) | TSHRMEN1KMT2AALDH1A1NPSR1 | |
| SCHEMBL3589255 | 0.77 | KDM2B (0.39) | TSHROPRM1TP53GNAI3GNAO1 | |
| SCHEMBL24127742 | 0.76 | L3MBTL3 (0.38) | TSHRMEN1KMT2AALDH1A1L3MBTL3 | |
| SCHEMBL8362610 | 0.75 | OPRM1 (0.34) | OPRL1OPRM1 | |
| SCHEMBL19101360 | 0.75 | GNAI3 (0.38) | OPRM1TP53GNAI3GNAO1GNAI1 | |
| SCHEMBL19481207 | 0.75 | GNAI3 (0.38) | OPRM1TP53GNAI3GNAO1GNAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180111939-A1 | 7-(MORPHOLIN-4-YL)PYRAZOLE[1,5-A]PYRIMIDINE DERIVATIVES WHICH ARE USEFUL FOR THE TREATMENT OF IMMUNE OR INFALMMATORY DISEASES OR CANCER | CELON PHARMA S.A. (PL) | 2018-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180111939-A1 | 7-(MORPHOLIN-4-YL)PYRAZOLE[1,5-A]PYRIMIDINE DERIVATIVES WHICH ARE USEFUL FOR THE TREATMENT OF IMMUNE OR INFALMMATORY DISEASES OR CANCER | AFF2, INF2, AFF1 | TSHR 1324/4885MEN1 194/4885KMT2A 3221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.